Tesamorelin
A growth hormone-releasing hormone analog approved in the United States for reducing excess abdominal fat in certain adults with HIV-associated lipodystrophy.
Also referenced as: Egrifta, Egrifta SV
Also appears in: Muscle Growth
This peptide maps to at least one regulated medical product or label context in the United States.
Primary lane: Growth Hormone. Also surfaces under Muscle Growth for browsing and discovery.
Egrifta, Egrifta SV
FDA label signal · 23 trials · 85 PubMed results
What tesamorelin is
Tesamorelin is a synthetic analog of growth hormone-releasing hormone. In the United States, it is best known through Egrifta and Egrifta SV, which are FDA-approved for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.
Why it matters on this site
Tesamorelin is useful because it reminds people that not every peptide conversation is really about gray-market research compounds. Some peptides have narrow, specific, fully regulated indications that should not be blurred into broader enhancement or physique chatter.
Regulatory context
FDA labeling for tesamorelin products states the approved indication as reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy:
Practical reading note
Tesamorelin gets discussed far outside its actual approved use. That makes it a good test case for how to read peptide claims carefully:
- approved indication does not equal general-purpose body-composition approval
- mechanism does not equal outcome in every population
- community enthusiasm does not replace label language
Why we include it
On PeptideBenchmark, tesamorelin is less about trend-chasing and more about helping readers separate:
- FDA-approved peptide medicines
- investigational drugs
- and research-market compounds discussed under the same broad “peptide” umbrella